{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:47:19Z","timestamp":1792010839312,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004351","name":"Sultan Qaboos University","doi-asserted-by":"publisher","award":["IG\/MED\/PHYS\/24\/01"],"award-info":[{"award-number":["IG\/MED\/PHYS\/24\/01"]}],"id":[{"id":"10.13039\/501100004351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pflugers Arch - Eur J Physiol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Type 2 long QT syndrome (LQT2) increases the risk of cardiac arrest and sudden death due to reduced rapid delayed rectifier potassium currents (IKr) in the heart. Caused by loss-of-function genetic variants in the hERG K\n                    <jats:sup>+<\/jats:sup>\n                    channel, LQT2 might benefit from variant-targeted therapy approaches. T1019PfsX38 and Q1070X are LQT2-causing variants reported in Oman and Saudi Arabia. Although nonsense-mediated mRNA decay (NMD) has been proposed to contribute to reduced expression of these truncating variants, it remains unclear whether residual mutant hERG channel function can be pharmacologically enhanced. We used the patch-clamp technique and examined the effects of the hERG potentiator NS1643 on wild-type-, T1019PfsX38- and Q1070X-hERG channels expressed in HEK293 cells. We started by assessing the response of these variants under the influence of a ventricular action potential clamp protocol, then used additional protocols to elucidate the drug\u2019s mechanism of action. NS1643 [10 \u00b5M] enhanced the repolarization currents in wild-type-, T1019PfsX38- and Q1070X-expressing cells. Its effect was associated with accelerated activation rates and a negative shift in the voltage dependence of activation. In addition, NS1643 suppressed fast deactivation transitions. We conclude that the functions of T1019PfsX38- and Q1070X-hERG channels can be augmented by hERG potentiators if NMD is incomplete, which may facilitate the development of a mechanism-based rescue approach.\n                  <\/jats:p>","DOI":"10.1007\/s00424-026-03215-7","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:20:32Z","timestamp":1790925632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NS1643 enhances the activity of T1019PfsX38 and Q1070X hERG channels associated with long QT syndrome type 2"],"prefix":"10.1007","volume":"478","author":[{"given":"Majid K.","family":"Al Salmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Al Kharusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Al Rawahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulayma","family":"Albarwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"2","key":"3215_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0092-8674(95)90340-2","volume":"81","author":"MC Sanguinetti","year":"1995","unstructured":"Sanguinetti MC, Jiang C, Curran ME, Keating MT (1995) A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel. Cell 81(2):299\u2013307. https:\/\/doi.org\/10.1016\/0092-8674(95)90340-2","journal-title":"Cell"},{"issue":"5","key":"3215_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/0092-8674(95)90358-5","volume":"80","author":"ME Curran","year":"1995","unstructured":"Curran ME, Splawski I, Timothy KW, Vincen GM, Green ED, Keating MT (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80(5):795\u2013803. https:\/\/doi.org\/10.1016\/0092-8674(95)90358-5","journal-title":"Cell"},{"issue":"1","key":"3215_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1161\/01.CIR.0000109482.92774.3A","volume":"109","author":"R Brugada","year":"2004","unstructured":"Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM, Brugada J, Pollevick GD, Wolpert C, Burashnikov E, Matsuo K, Wu YS, Guerchicoff A, Bianchi F, Giustetto C, Schimpf R, Brugada P, Antzelevitch C (2004) Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109(1):30\u201335. https:\/\/doi.org\/10.1161\/01.CIR.0000109482.92774.3A","journal-title":"Circulation"},{"issue":"11","key":"3215_CR4","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1161\/01.RES.0000128561.28701.ea","volume":"94","author":"BP Delisle","year":"2004","unstructured":"Delisle BP, Anson BD, Rajamani S, January CT (2004) Biology of cardiac arrhythmias: ion channel protein trafficking. Circ Res 94(11):1418\u20131428. https:\/\/doi.org\/10.1161\/01.RES.0000128561.28701.ea","journal-title":"Circ Res"},{"issue":"11","key":"3215_CR5","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/HUMU.21106","volume":"30","author":"PL Hedley","year":"2009","unstructured":"Hedley PL, J\u00f8rgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, Kanters JK, Corfield VA, Christiansen M (2009) The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat 30(11):1486\u20131511. https:\/\/doi.org\/10.1002\/HUMU.21106","journal-title":"Hum Mutat"},{"issue":"1","key":"3215_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0002-9343(01)01011-7","volume":"112","author":"IA Khan","year":"2002","unstructured":"Khan IA (2002) Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med 112(1):58\u201366. https:\/\/doi.org\/10.1016\/S0002-9343(01)01011-7","journal-title":"Am J Med"},{"key":"3215_CR7","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/J.TOXLET.2007.05.032","volume":"172","author":"J Mitcheson","year":"2007","unstructured":"Mitcheson J (2007) The structural basis of drug induced long QT syndrome. Toxicol Lett 172:S4. https:\/\/doi.org\/10.1016\/J.TOXLET.2007.05.032","journal-title":"Toxicol Lett"},{"key":"3215_CR8","doi-asserted-by":"crossref","unstructured":"Kiehn J, Lacerda AE, Wible B, Brown AM (1996) Molecular physiology and pharmacology of HERG: Single-channel currents and block by dofetilide. Circulation 94(10):2572\u20132579. https:\/\/doi.org\/10.1161\/01.CIR.94.10.2572\/ASSET\/5BEDC201-1F91-4EB3-95BD-F8F890399354\/ASSETS\/GRAPHIC\/0010F9.JPEG","DOI":"10.1161\/01.CIR.94.10.2572"},{"issue":"4","key":"3215_CR9","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/JOA3.12741","volume":"38","author":"A El Harchi","year":"2022","unstructured":"El Harchi A, Brincourt O (2022) Pharmacological activation of the hERG K+ channel for the management of the long QT syndrome: a review. J Arrhythm 38(4):554\u2013569. https:\/\/doi.org\/10.1002\/JOA3.12741","journal-title":"J Arrhythm"},{"issue":"7","key":"3215_CR10","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/bjp.2008.191","volume":"154","author":"HR Lu","year":"2008","unstructured":"Lu HR, Vlaminckx E, Hermans AN, Rohrbacher J, Van Ammel K, Towart R, Pugsley M, Gallacher DJ (2008) Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B guidelines. Br J Pharmacol 154(7):1427\u20131438. https:\/\/doi.org\/10.1038\/bjp.2008.191","journal-title":"Br J Pharmacol"},{"issue":"3","key":"3215_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1161\/CIRCULATIONAHA.105.570200","volume":"113","author":"CL Anderson","year":"2006","unstructured":"Anderson CL, Delisle BP, Anson BD, Kilby JA, Will ML, Tester DJ, Gong Q, Zhou Z, Ackerman MJ, January CT (2006) Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 113(3):365\u2013373. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.570200","journal-title":"Circulation"},{"issue":"33","key":"3215_CR12","doi-asserted-by":"publisher","first-page":"21061","DOI":"10.1074\/JBC.273.33.21061","volume":"273","author":"Z Zhou","year":"1998","unstructured":"Zhou Z, Gong Q, Epstein ML, January CT (1998) HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects. J Biol Chem 273(33):21061\u201321066. https:\/\/doi.org\/10.1074\/JBC.273.33.21061","journal-title":"J Biol Chem"},{"issue":"Pt 17","key":"3215_CR13","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1113\/JPHYSIOL.2010.194670","volume":"588","author":"M Perry","year":"2010","unstructured":"Perry M, Sanguinetti M, Mitcheson J (2010) Revealing the structural basis of action of hERG potassium channel activators and blockers. J Physiol 588(Pt 17):3157\u20133167. https:\/\/doi.org\/10.1113\/JPHYSIOL.2010.194670","journal-title":"J Physiol"},{"issue":"9","key":"3215_CR14","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.hrthm.2009.05.021","volume":"6","author":"JD Kapplinger","year":"2009","unstructured":"Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD, Wilde AA, Ackerman MJ (2009) Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm 6(9):1297\u20131303. https:\/\/doi.org\/10.1016\/j.hrthm.2009.05.021","journal-title":"Heart Rhythm"},{"key":"3215_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6535","volume":"5","author":"CL Anderson","year":"2014","unstructured":"Anderson CL, Kuzmicki CE, Childs RR, Hintz CJ, Delisle BP, January CT (2014) Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome. Nat Commun 5:5535. https:\/\/doi.org\/10.1038\/ncomms6535","journal-title":"Nat Commun"},{"issue":"23","key":"3215_CR16","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1161\/CIRCULATIONAHA.124.069828","volume":"150","author":"MJ O\u2019Neill","year":"2024","unstructured":"O\u2019Neill MJ, Ng CA, Aizawa T, Sala L, Bains S, Winbo A, Ullah R, Shen Q, Tan CY, Kozek K, Vanags LR, Mitchell DW, Shen A, Wada Y, Kashiwa A, Crotti L, Dagradi F, Musu G, Spazzolini C, Neves R, Kroncke BM (2024) Multiplexed Assays of Variant Effect and Automated Patch Clamping Improve KCNH2-LQTS Variant Classification and Cardiac Event Risk Stratification. Circulation 150(23):1869\u20131881. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069828","journal-title":"Circulation"},{"key":"3215_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neubiorev.2013.10.016","volume":"46","author":"LS Nguyen","year":"2014","unstructured":"Nguyen LS, Wilkinson MF, Gecz J (2014) Nonsense-mediated mRNA decay: inter-individual variability and human disease. Neurosci Biobehav Rev 46:175\u2013186. https:\/\/doi.org\/10.1016\/j.neubiorev.2013.10.016","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"3215_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.37616\/2212-5043.1441","volume":"37","author":"K Al Azri","year":"2025","unstructured":"Al Azri K, Al Abri I, Al Shehhi M, Al Hinai M, Al Amri T, Al Sheala N, Al Shabibi A, Al Azri K, Al Abri I, Al Shehhi M, Al Hinai M, Al Amri T, Al Sheala N, Al Shabibi A (2025) Demographics, clinical features and genetics of common inherited arrhythmias in Oman. J Saudi Heart Assoc 37(3):4. https:\/\/doi.org\/10.37616\/2212-5043.1441","journal-title":"J Saudi Heart Assoc"},{"issue":"1","key":"3215_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijchv.2014.06.001","volume":"4","author":"KS Al Senaidi","year":"2014","unstructured":"Al Senaidi KS, Wang G, Zhang L, Beer DA, AlFarqani AM, AlMaskaryi SN, Penny DJ, Kowey PR, Fan Y (2014) Long QT syndrome, cardiovascular anomaly and findings in ECG-guided genetic testing. IJC Heart Vessels 4(1):122\u2013128. https:\/\/doi.org\/10.1016\/j.ijchv.2014.06.001","journal-title":"IJC Heart Vessels"},{"issue":"4","key":"3215_CR20","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/J.HRTHM.2008.01.020","volume":"5","author":"ZA Bhuiyan","year":"2008","unstructured":"Bhuiyan ZA, Momenah TS, Gong Q, Amin AS, Al Ghamdi S, Carvalho JS, Homfray T, Mannens MMAM, Zhou Z, Wilde AAM (2008) Recurrent intrauterine fetal loss due to near absence of HERG: clinical and functional characterization of a homozygous nonsense HERG Q1070X mutation. Heart Rhythm 5(4):553\u2013561. https:\/\/doi.org\/10.1016\/J.HRTHM.2008.01.020","journal-title":"Heart Rhythm"},{"issue":"1","key":"3215_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.yjmcc.2010.10.022","volume":"50","author":"Q Gong","year":"2011","unstructured":"Gong Q, Stump MR, Zhou Z (2011) Inhibition of nonsense-mediated mRNA decay by antisense morpholino oligonucleotides restores functional expression of hERG nonsense and frameshift mutations in long-QT syndrome. J Mol Cell Cardiol 50(1):223\u2013229. https:\/\/doi.org\/10.1016\/j.yjmcc.2010.10.022","journal-title":"J Mol Cell Cardiol"},{"issue":"8","key":"3215_CR22","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/J.HRTHM.2011.03.039","volume":"8","author":"IG Zarraga","year":"2011","unstructured":"Zarraga IG, Zhang L, Stump MR, Gong Q, Vincent GM, Zhou Z (2011) Nonsense-mediated mRNA decay caused by a frameshift mutation in a large kindred of type 2 long QT syndrome. Heart Rhythm 8(8):1200\u20131206. https:\/\/doi.org\/10.1016\/J.HRTHM.2011.03.039","journal-title":"Heart Rhythm"},{"issue":"14","key":"3215_CR23","doi-asserted-by":"publisher","DOI":"10.14814\/PHY2.15341","volume":"10","author":"MK Al Salmani","year":"2022","unstructured":"Al Salmani MK, Tavakoli R, Zaman W, Al Harrasi A (2022) Multiple mechanisms underlie reduced potassium conductance in the p.T1019PfsX38 variant of hERG. Physiol Rep 10(14):e15341. https:\/\/doi.org\/10.14814\/PHY2.15341","journal-title":"Physiol Rep"},{"issue":"2","key":"3215_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1124\/mol.105.019943","volume":"69","author":"O Casis","year":"2006","unstructured":"Casis O, Olesen SP, Sanguinetti MC (2006) Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Mol Pharmacol 69(2):658\u2013665. https:\/\/doi.org\/10.1124\/mol.105.019943","journal-title":"Mol Pharmacol"},{"issue":"6","key":"3215_CR25","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.bpj.2014.12.055","volume":"108","author":"J Guo","year":"2015","unstructured":"Guo J, Cheng YM, Lees-Miller JP, Perissinotti LL, Claydon TW, Hull CM, Thouta S, Roach DE, Durdagi S, Noskov SY, Duff HJ (2015) NS1643 Interacts around L529 of hERG to alter voltage sensor movement on the path to activation. Biophys J 108(6):1400\u20131413. https:\/\/doi.org\/10.1016\/j.bpj.2014.12.055","journal-title":"Biophys J"},{"issue":"6","key":"3215_CR26","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.bpj.2014.12.056","volume":"108","author":"LL Perissinotti","year":"2015","unstructured":"Perissinotti LL, Guo J, De Biase PM, Clancy CE, Duff HJ, Noskov SY (2015) Kinetic model for NS1643 drug activation of WT and L529I variants of Kv11.1 (hERG1) potassium channel. Biophys J 108(6):1414\u20131424. https:\/\/doi.org\/10.1016\/j.bpj.2014.12.056","journal-title":"Biophys J"},{"issue":"2","key":"3215_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/J.VASCN.2010.02.007","volume":"61","author":"JT Milnes","year":"2010","unstructured":"Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC (2010) Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37\u00b0C: Cisapride versus dofetilide. J Pharmacol Toxicol Methods 61(2):178\u2013191. https:\/\/doi.org\/10.1016\/J.VASCN.2010.02.007","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"6","key":"3215_CR28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/S004240050713","volume":"436","author":"JC Hancox","year":"1998","unstructured":"Hancox JC, Levi AJ, Witchel HJ (1998) Time course and voltage dependence of expressed HERG current compared with native \u201drapid\u201d delayed rectifier K current during the cardiac ventricular action potential. Pflugers Arch 436(6):843\u2013853. https:\/\/doi.org\/10.1007\/S004240050713","journal-title":"Pflugers Arch"},{"issue":"5220","key":"3215_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1126\/SCIENCE.7604285","volume":"269","author":"MC Trudeau","year":"1995","unstructured":"Trudeau MC, Warmke JW, Ganetzky B, Robertson GA (1995) HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269(5220):92\u201395. https:\/\/doi.org\/10.1126\/SCIENCE.7604285","journal-title":"Science"},{"key":"3215_CR30","doi-asserted-by":"publisher","unstructured":"Al Salmani MK, Sondo E, Balut C, Sheppard DN, Singh AK, Pedemonte N (2020) Molecular Physiology and Pharmacology of the Cystic Fibrosis Transmembrane Conductance Regulator. Studies of Epithelial Transporters and Ion Channels. Springer, Cham, pp 605\u2013670. https:\/\/doi.org\/10.1007\/978-3-030-55454-5_16","DOI":"10.1007\/978-3-030-55454-5_16"},{"issue":"2","key":"3215_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.neuropharm.2007.05.009","volume":"53","author":"P Elmedyb","year":"2007","unstructured":"Elmedyb P, Olesen SP, Grunnet M (2007) Activation of ERG2 potassium channels by the diphenylurea NS1643. Neuropharmacology 53(2):283\u2013294. https:\/\/doi.org\/10.1016\/j.neuropharm.2007.05.009","journal-title":"Neuropharmacology"},{"issue":"3","key":"3215_CR32","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1476-5381.2010.00897.x","volume":"161","author":"AP Larsen","year":"2010","unstructured":"Larsen AP, Bentzen BH, Grunnet M (2010) Differential effects of Kv11.1 activators on Kv11.1a, Kv11.1b and Kv11.1a\/Kv11.1b channels. Br J Pharmacol 161(3):614\u2013628. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00897.x","journal-title":"Br J Pharmacol"},{"key":"3215_CR33","doi-asserted-by":"publisher","first-page":"329542","DOI":"10.3389\/FNMOL.2018.00011\/BIBTEX","volume":"11","author":"M Dierich","year":"2018","unstructured":"Dierich M, Evers S, Wilke BU, Leitner MG (2018) Inverse modulation of neuronal Kv 12.1 and kv 11.1 channels by 4-aminopyridine and NS1643. Front Mol Neurosci 11:329542. https:\/\/doi.org\/10.3389\/FNMOL.2018.00011\/BIBTEX","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"3215_CR34","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1182\/BLOOD.V97.5.1451","volume":"97","author":"P Bennekou","year":"2001","unstructured":"Bennekou P, De Franceschi L, Pedersen O, Lian L, Asakura T, Evans G, Brugnara C, Christophersen P (2001) Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease. Blood 97(5):1451\u20131457. https:\/\/doi.org\/10.1182\/BLOOD.V97.5.1451","journal-title":"Blood"},{"issue":"4","key":"3215_CR35","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1124\/MOL.106.026492","volume":"70","author":"RS Hansen","year":"2006","unstructured":"Hansen RS, Diness TG, Christ T, Wettwer E, Ravens U, Olesen SP, Grunnet M (2006) Biophysical Characterization of the New Human Ether-A-Go-Go-Related Gene Channel Opener NS3623 [N-(4-Bromo-2-(1H-tetrazol-5-yl)-phenyl)-N\u2032-(3\u2032-trifluoromethylphenyl)urea]. Mol Pharmacol 70(4):1319\u20131329. https:\/\/doi.org\/10.1124\/MOL.106.026492","journal-title":"Mol Pharmacol"}],"container-title":["Pfl\u00fcgers Archiv - European Journal of Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00424-026-03215-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00424-026-03215-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00424-026-03215-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:10:55Z","timestamp":1792008655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00424-026-03215-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3215"],"URL":"https:\/\/doi.org\/10.1007\/s00424-026-03215-7","relation":{},"ISSN":["0031-6768","1432-2013"],"issn-type":[{"value":"0031-6768","type":"print"},{"value":"1432-2013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"84"}}